If you only want the short version. For four or five compounds there is a real answer, because somebody ran a trial and measured something.
For most of what is sold, there is no answer at all. The week-by-week timelines on vendor pages were written by the people selling the vials.
Almost no trial is designed to find out when a drug starts working. Trials measure a specific thing at a fixed point, usually months in, and that number gets repeated as though it were an onset time.
And the compounds people most want a timeline for, the ones for injuries and healing, are the ones where you are least able to tell.
"Working" means three different things
People asking this question usually mean one of three things, and they have different timelines and different levels of certainty.
Something measurable changed
A blood marker moved. Only this version can be verified, and for the growth hormone compounds it is the fastest. IGF-1 rises within one to two weeks of daily tesamorelin, and MK-677 produced its largest measured rise at the two-week mark in an eight-week trial.
Something visible changed
Weight on a scale, fat on a scan, skin in a photograph. Slower, and still checkable if you measure the same way each time.
Something felt different
Energy, sleep, joint pain, recovery. Most people mean this one. It appears fastest and it cannot be verified, because expectation produces the same thing reliably in placebo arms.
Vendor timelines are written about the third and quoted as though they described the first.
Some things happen immediately, and they are usually side effects
There is an exception to all three, and it produces the opposite error.
A few compounds do something on the first dose. PT-141 acts within hours. Melanotan II commonly produces flushing and nausea straight away. The GLP-1 drugs produce nausea in the first week for a large share of people.
None of that is the effect anyone is paying for. It is a receptor being occupied, which is evidence the compound is present and active, and not evidence that the outcome you want is on its way.
The confusion runs both directions and this is the direction nobody warns about. Feeling nothing after one dose tells you very little. Feeling something after one dose tells you almost as little, and it feels like proof.
The compounds with a real answer
Five, and the numbers below are trial endpoints, not onset times.
| Compound | What was measured | When |
|---|---|---|
| Semaglutide | Weight | Loss detectable at the first assessment, week 4; continuing to about week 60; 14.9% at week 68 |
| Tirzepatide | Weight | Primary endpoint at 72 weeks |
| Retatrutide | Weight | Primary endpoint at 80 weeks |
| Tesamorelin | Visceral fat by CT | Primary endpoint at 26 weeks. IGF-1 rises within 1 to 2 weeks |
| MK-677 | GH and IGF-1 | Largest rise at 2 weeks, in an 8-week trial |
| GHK-Cu, topical | Skin appearance and photodamage | Trials ran 12 weeks |
The lab marker moves long before anything you can see. Tesamorelin raises IGF-1 in a fortnight and its visceral fat endpoint is six months. Someone judging tesamorelin at week three has picked both the wrong measure and the wrong moment.
And the GLP-1 timelines are partly a dosing artefact. The schedule steps up over sixteen to twenty weeks, so a person in month two is not yet on the dose the trial was reporting, and slow early results are the protocol working as designed.
The problem with the question itself
Clinical trials are built to answer whether a drug beats placebo on a defined measure at a defined moment. Finding out when people start noticing things is a different study, and it is rarely the one that gets run.
So "the trial ran 68 weeks" tells you when the tape was measured. When the effect began is a separate question, and usually nobody looked.
The exceptions are trials that took repeated measurements along the way. That is why a semaglutide figure exists for week 4, and why no retatrutide equivalent does.
That explains something odd about vendor pages. They are more precise than the science. A product page will tell you week 2 for better sleep, week 4 for joint relief, week 8 for visible change. No trial produced any of that. Real timelines arrive with ranges, confidence intervals and a list of what was not measured, and none of those survive the trip to a product page.
For most of the library, there is nothing
BPC-157, TB-500, KPV, MOTS-c, epitalon, ipamorelin, CJC-1295, most of what gets sold: no human trial has measured how long any of them takes to do anything.
That is not a gap in this page. It is the state of the evidence, and our guide on why most peptides have no human evidence covers how four different situations produce the same blank space.
What exists instead is a set of numbers that circulate. Two to four weeks for BPC-157. Four to six for TB-500. Eight weeks before you judge anything. Follow any of them back and you arrive at a product page.
The trap with the healing compounds
More readers are in this situation than in any other on this page, and it goes largely undiscussed.
People do not start a healing peptide at a random moment. They start it when the pain is worst, which is when they finally decide to try something.
Most injuries improve from their worst point regardless of what you do. Tendons, strains, joint flare-ups: the natural course is to get better, and the improvement is fastest right after the worst of it. So somebody who starts BPC-157 at peak pain and feels better in three weeks has produced exactly the result they would have produced doing nothing.
Statisticians call it regression to the mean, and it is the reason injury treatments need control groups more than almost anything else in medicine. Without one, you cannot separate recovery from whatever you happened to be taking at the time.
None of that proves these compounds do nothing. What it establishes is that personal experience cannot tell you either way, and that a compound with no trial behind it is being judged by the one method least able to judge it.
The other timeline: when it stops working
Asked almost as often, and there is one real measurement.
Twelve healthy older adults injected hexarelin twice daily for sixteen weeks. Growth hormone output fell from 19.1 at baseline to 13.1 after a single week, 12.3 at four weeks and 10.5 at sixteen. Four weeks off restored it.
Those figures are the only measured desensitisation data in this family, it comes from one small study of one compound, and the fall inside the first week is what makes it interesting. Receptor systems adapt to constant signalling, and the compounds that work by asking your body to release something are the ones most exposed to it.
Our growth hormone guide covers what that does to the cycling advice. The eight-weeks-on schedule circulating everywhere rests on this one study, of a different compound, in twelve people.
And when you stop taking it
What happens after you stop changes the arithmetic more than the onset time does.
For the GLP-1 drugs it is documented. In the STEP 1 extension, people who had lost 17.3% of their body weight regained 11.6 percentage points of it in the year after stopping, with the cardiometabolic improvements drifting back alongside. Tesamorelin's visceral fat returns toward baseline within weeks of stopping. Melanotan pigment fades over weeks to months.
For everything without trial data, nobody has measured it either.
For several of these compounds the effect and the treatment end together, so how long it lasts after you stop is worth as much thought as how long it takes to start. Our guide on what peptide therapy costs works through what that does to a monthly budget with no end date.
When impatience is the actual hazard
For most compounds a slow result is disappointing. For a few, chasing it is the risk.
Someone escalating melanotan II because the tan is slow is moving toward the effects listed at the top of that guide, which include reactions serious enough for intensive care. Someone stepping up a GLP-1 faster than the titration schedule gets the vomiting and dehydration the schedule exists to prevent.
The schedules that exist were chosen for reasons, and running ahead of one because nothing has happened yet is how a timeline question becomes a safety question.
How to tell whether anything is happening
If you are going to run the experiment on yourself, run it properly. Four things make the difference between an observation and a story.
Measure a baseline before you start
Whatever you plan to judge it on, record it first. Weight, a photograph in the same light, a lab panel, a pain score written down. Memory drifts toward whatever you expect, which is what makes it useless as a starting point.
Change one thing at a time
Two compounds started in the same week produce one result you cannot attribute. The same argument applies to blends, where a manufacturer chose the ratio and the components cannot be separated.
Use the trial's timeframe
Tesamorelin's endpoint was six months. Judging a growth hormone compound at three weeks tells you nothing except that three weeks has passed.
Treat an early change with suspicion
The first fortnight is where expectation is strongest, and where almost nothing measurable has had time to happen. A change in that window can be entirely real to you and still tell you nothing about the compound.
Our guide on working out cost per dose belongs alongside this one, because a timeline is also a bill. How many months you are prepared to pay for is usually the number that settles it.
What this page cannot tell you
How long any compound takes to work for you. Even where trial data exists, it describes averages in a selected population, and the people in those trials were not you.
Whether a compound with no trial data works at all. The absence of a timeline is not evidence that nothing happens; it is evidence that nobody has measured it.
When to stop. That depends on what you are treating, what else you are doing, and a clinician who knows your situation.
Common questions
How long does BPC-157 take to work?
No human trial has measured it. The two-to-four-week figure that circulates comes from vendor pages and community reports, not from published research, and injury recovery is the situation where personal experience is least reliable.
How long before I see weight loss on semaglutide?
Trial data showed measurable loss at the first assessment point, four weeks in, with the total continuing to build until around week 60. The dose steps up over the first four months, so early results are slower by design.
Should I feel something on the first injection?
For most compounds there is nothing you should expect to feel immediately. Some produce noticeable side effects early, and that is a different thing from the compound working. One dose with nothing to report is uninformative either way.
Why do vendor sites give week-by-week timelines?
Because they are selling something and a schedule is reassuring. Those numbers are more precise than any published research, which is the clue. Real timelines come with ranges and caveats.
How long should I give it before stopping?
That depends on the compound and what you are measuring. For the ones with trials, the endpoint gives you a benchmark: six months for tesamorelin, twelve weeks for topical GHK-Cu. For everything else there is no benchmark at all, which is the thing to weigh before committing to an indefinite spend.
Does it work faster at a higher dose?
Not reliably, and the assumption causes harm. Higher doses are where the reported adverse events cluster, and for the compounds with trials the schedules were chosen deliberately, not as a floor to build on.
I felt better within days. Does that mean it is working?
You felt better, and that is all it establishes. Expectation effects are strongest early and are strongest for subjective outcomes like energy, sleep and pain, which is what people usually report. It might also be the compound. There is no way to tell from a single person's experience, which is what trials exist for.
Do peptides stop working over time?
There is one measurement. Twelve people injecting hexarelin twice daily saw growth hormone output fall by roughly a third within a week, and recover after four weeks off. That is one small study of one compound, and it is the only measured desensitisation data in the growth hormone family.
What happens when I stop?
For the GLP-1 drugs, most of the weight comes back: two-thirds of it within a year in the trial extension that measured it. Tesamorelin's visceral fat returns toward baseline within weeks. For compounds with no trial data, nobody has measured what happens after stopping either.
I felt flushing on the first injection. Is that it working?
Flushing means the compound reached a receptor. Several compounds produce immediate effects, and those effects are usually side effects instead of the outcome you are after. Immediate feedback feels like proof without being any.
Does the timeline reset if I miss a dose?
For compounds with long half-lives, a missed dose barely registers. For short-acting ones taken daily, a gap is a gap. Neither resets anything, and there is no published evidence for the restart-the-clock advice that circulates.
Sources
[^1]: Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 2021;384(11):989-1002. Peer-reviewed randomised controlled trial. STEP 1. Mean weight change of 14.9% at week 68 with semaglutide 2.4 mg against 2.4% with placebo. Weight loss was detectable from the first post-randomisation assessment and continued through approximately week 60 before plateauing.
[^2]: Falutz J, et al. Phase 3 trials of tesamorelin in HIV-associated lipodystrophy, 2008 and 2010, and the associated trial records. Peer-reviewed trials. Primary endpoint was change in visceral adipose tissue measured by CT at 26 weeks. Extension studies ran to 52 weeks. Visceral fat returns toward baseline after treatment stops. The observation that serum IGF-1 rises within one to two weeks of daily dosing is widely reported in clinical summaries; the specific timepoint should be confirmed against the trial publications before publication.
[^3]: Sinha DK, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology, 2019. Peer-reviewed review, read at source. Describes a trial of 24 men aged 19 to 49 with BMI over 30, given 25 mg ibutamoren daily or placebo for 8 weeks. The largest increase in serum GH peak and area under the curve was observed at 2 weeks, with serum IGF-1 and IGFBP-3 also significantly increased at that point.
[^4]: Trial durations for tirzepatide and retatrutide. See our comparison of the three GLP-1 compounds, which carries the primary citations. SURMOUNT trials for tirzepatide reported at 72 weeks; TRIUMPH-1 for retatrutide at 80 weeks.
[^5]: Topical GHK-Cu trial durations. See our GHK-Cu guide, which carries the primary citations. The controlled human trials of topical formulations ran for 12 weeks.
[^6]: Hexarelin desensitisation study. See our growth hormone peptides guide, which carries the primary citation. Twelve healthy older adults, twice-daily dosing over sixteen weeks, growth hormone output falling from 19.1 at baseline to 13.1 at one week, 12.3 at four weeks and 10.5 at sixteen, recovering after four weeks off treatment.
[^7]: Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism 2022;24(8):1553-1564. Peer-reviewed trial extension, abstract read at source. Participants regained 11.6 percentage points of the 17.3% lost by week 68, in the year after withdrawal, with cardiometabolic improvements reverting toward baseline.
[^8]: Regression to the mean in the assessment of injury treatments. Statistical principle. A source establishing the effect in the context of pain and musculoskeletal outcomes should be added before publication; the argument in this section is standard and should not rest on assertion.